Trial Outcomes & Findings for A Study of LY3084077 in Healthy Participants (NCT NCT01846702)
NCT ID: NCT01846702
Last Updated: 2018-07-30
Results Overview
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
43 participants
Primary outcome timeframe
Pre-dose, Up to Day 190
Results posted on
2018-07-30
Participant Flow
Participant milestones
| Measure |
Placebo Cohort 1
Single dose of placebo matching LY3084077 administered subcutaneously (SC).
|
LY3084077 Cohort 2
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
3 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 4
10 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 5
30 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 6
100 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 7
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
6
|
6
|
7
|
6
|
6
|
6
|
6
|
|
Overall Study
Received at Least 1 Dose of Study Drug
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
|
Overall Study
COMPLETED
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study of LY3084077 in Healthy Participants
Baseline characteristics by cohort
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered subcutaneously (SC).
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3074077 administered SC.
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3074077 administered SC.
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3074077 administered SC.
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3074077 administered SC.
|
Total
n=42 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
35.7 years
STANDARD_DEVIATION 14 • n=5 Participants
|
30.7 years
STANDARD_DEVIATION 13.2 • n=7 Participants
|
34.5 years
STANDARD_DEVIATION 11.2 • n=5 Participants
|
32.7 years
STANDARD_DEVIATION 7.4 • n=4 Participants
|
40.7 years
STANDARD_DEVIATION 12.6 • n=21 Participants
|
30.5 years
STANDARD_DEVIATION 5.0 • n=10 Participants
|
36.3 years
STANDARD_DEVIATION 4.8 • n=115 Participants
|
34.4 years
STANDARD_DEVIATION 10.2 • n=24 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
2 Participants
n=24 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
6 Participants
n=10 Participants
|
6 Participants
n=115 Participants
|
40 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
6 Participants
n=10 Participants
|
6 Participants
n=115 Participants
|
42 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
6 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
6 Participants
n=10 Participants
|
6 Participants
n=115 Participants
|
40 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
2 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=24 Participants
|
|
Region of Enrollment
Singapore
|
6 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
6 Participants
n=10 Participants
|
6 Participants
n=115 Participants
|
42 Participants
n=24 Participants
|
PRIMARY outcome
Timeframe: Pre-dose, Up to Day 190Population: All randomized participants who received at least one dose of study drug.
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
|
1 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Day 1 and Day 29: Predose, 2,4,8,12,24,36,48,72,96,120,168,336 hours post dosePopulation: All randomized participants who received at least one dose of study drug and had evaluable PK data.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=2 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=5 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=4 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration Curve Zero to Infinity (AUC[0-∞]) GLP1-Fc Domain of LY3084077
|
NA microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation NA
Cohort 1 was not calculable due to samples from placebo treated participants were not analyzed.
|
NA microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation NA
Cohort 2 was not calculable due to concentration level was below quantification limits.
|
8.74 microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation 13
|
17.9 microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation 42
|
61.8 microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation 34
|
248 microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation 221
|
249 microgram*hour/milliliter (μg•hr/mL)
Geometric Coefficient of Variation 20
|
SECONDARY outcome
Timeframe: Day 1 and Day 29: Predose, 2,4,8,12,24,36,48,72,96,120,168,336 hours post dosePopulation: All randomized participants who received at least one dose of study drug and had evaluable PK data.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=4 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
PK: Maximum Concentration (Cmax) GLP1-Fc Domain of LY3084077
|
NA microgram/milliliter (μg/mL)
Geometric Coefficient of Variation NA
Cohort 1 was not calculable due to samples from placebo treated participants were not analyzed.
|
NA microgram/milliliter (μg/mL)
Geometric Coefficient of Variation NA
Cohort 2 was not calculable due to concentration level was below quantification limits.
|
0.0428 microgram/milliliter (μg/mL)
Geometric Coefficient of Variation 53
|
0.0745 microgram/milliliter (μg/mL)
Geometric Coefficient of Variation 24
|
0.188 microgram/milliliter (μg/mL)
Geometric Coefficient of Variation 78
|
1.14 microgram/milliliter (μg/mL)
Geometric Coefficient of Variation 79
|
1.23 microgram/milliliter (μg/mL)
Geometric Coefficient of Variation 48
|
SECONDARY outcome
Timeframe: Baseline, Up to Day 15Population: All randomized participants who received at least one dose of study drug and had evaluable fasting triglycerides data.
Percent change=(measure at time t-measure at baseline)/measure at baseline\*100%). Least Square Means (LS means) were calculated using MMRM analysis adjusting for the random effect of participant, effect of baseline, and fixed categorical effects of treatment, visit, and treatment-by-visit interaction.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Pharmacodynamics (PD): Percent Change From Baseline in Fasting Triglycerides
|
-23.7 percent
Standard Deviation 12.8
|
-13.7 percent
Standard Deviation 12.8
|
-35.3 percent
Standard Deviation 12.6
|
-30.4 percent
Standard Deviation 12.6
|
-23.8 percent
Standard Deviation 13.6
|
-2.50 percent
Standard Deviation 14.2
|
-43.7 percent
Standard Deviation 13.0
|
SECONDARY outcome
Timeframe: Baseline, Up to Day 15Population: All randomized participants who received at least one dose of study drug and had evaluable fasting insulin data.
LS means were calculated using MMRM analysis adjusting for the random effect of participant, effect of baseline, and fixed categorical effects of treatment, visit, and treatment-by-visit interaction.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
PD: Change From Baseline in Fasting Insulin
|
-24.0 picomole/Liter (pmol/L)
Standard Error 8.23
|
-24.6 picomole/Liter (pmol/L)
Standard Error 8.55
|
-21.4 picomole/Liter (pmol/L)
Standard Error 8.41
|
4.90 picomole/Liter (pmol/L)
Standard Error 8.26
|
-28.4 picomole/Liter (pmol/L)
Standard Error 9.19
|
-11.9 picomole/Liter (pmol/L)
Standard Error 8.29
|
-26.6 picomole/Liter (pmol/L)
Standard Error 8.44
|
SECONDARY outcome
Timeframe: Baseline, Up to Day 15Population: Zero participants had weight measured and therefore change from baseline in weight was not calculable across all arms.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline, Day 2Population: All randomized participants who received at least one dose of study drug and had evaluable C-peptide AUC before and after a standard meal data.
LS means were calculated using MMRM analysis adjusting for the random effect of participant, effect of baseline, and fixed categorical effects of treatment, visit, and treatment-by-visit interaction.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
PD: Change From Baseline Up to Day 2 in Level of C-peptide AUC (Predose to 4 Hours) After a Standard Meal
|
-292 picomole*hour/Liter (pmol*h/L)
Standard Error 579
|
310 picomole*hour/Liter (pmol*h/L)
Standard Error 559
|
-157 picomole*hour/Liter (pmol*h/L)
Standard Error 579
|
1313 picomole*hour/Liter (pmol*h/L)
Standard Error 564
|
372 picomole*hour/Liter (pmol*h/L)
Standard Error 592
|
-192 picomole*hour/Liter (pmol*h/L)
Standard Error 564
|
973 picomole*hour/Liter (pmol*h/L)
Standard Error 568
|
SECONDARY outcome
Timeframe: Baseline, Day 2Population: All randomized participants who received at least one dose of study drug and had evaluable incremental glucose AUC before and after a standard meal data.
LS means were calculated using MMRM analysis adjusting for the random effect of participant, effect of baseline, and fixed categorical effects of treatment, visit, and treatment-by-visit interaction.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
PD: Change From Baseline to Day 2 Incremental AUC Level of Blood Glucose (Predose to 6 Hours) After a Standard Meal
|
-1.76 millomole*hour/Liter (mmol*h/L)
Standard Error 1.16
|
0.758 millomole*hour/Liter (mmol*h/L)
Standard Error 1.18
|
-0.202 millomole*hour/Liter (mmol*h/L)
Standard Error 1.14
|
-0.350 millomole*hour/Liter (mmol*h/L)
Standard Error 1.15
|
-2.14 millomole*hour/Liter (mmol*h/L)
Standard Error 1.13
|
-1.79 millomole*hour/Liter (mmol*h/L)
Standard Error 1.13
|
-1.82 millomole*hour/Liter (mmol*h/L)
Standard Error 1.15
|
SECONDARY outcome
Timeframe: Baseline, Up to Day 2Population: All randomized participants who received at least one dose of study drug and have evaluable fasting glucagon data.
LS means were calculated using MMRM analysis adjusting for the random effect of participant, effect of baseline, and fixed categorical effects of treatment, visit, and treatment-by-visit interaction.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
PD: Change From Baseline to Day 2 in Fasting Glucagon
|
3.17 pmol/L
Standard Error 1.98
|
0.940 pmol/L
Standard Error 1.96
|
2.38 pmol/L
Standard Error 1.98
|
-0.514 pmol/L
Standard Error 1.95
|
4.15 pmol/L
Standard Error 1.96
|
1.01 pmol/L
Standard Error 1.99
|
1.52 pmol/L
Standard Error 1.96
|
SECONDARY outcome
Timeframe: Pre-dose, Up to Day 190Population: All randomized participants who received at least one dose of study drug and had evaluable baseline and postbaseline antibody titers.
The number of participants with 1:4 baseline and postbaseline positive anti-LY3084077 antibody titers.
Outcome measures
| Measure |
Placebo Cohort 1
n=6 Participants
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 Participants
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 Participants
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 Participants
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 Participants
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 Participants
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 Participants
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Number of Participants Developing Anti-LY3084077 Antibodies
|
0 participants
|
1 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
0 participants
|
Adverse Events
Placebo Cohort 1
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
LY3084077 Cohort 2
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
LY3084077 Cohort 3
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LY3084077 Cohort 4
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
LY3084077 Cohort 5
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
LY3084077 Cohort 6
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
LY3084077 Cohort 7
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Placebo Cohort 1
n=6 participants at risk
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 participants at risk
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 participants at risk
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 participants at risk
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 participants at risk
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 participants at risk
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 participants at risk
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Gastritis
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
Other adverse events
| Measure |
Placebo Cohort 1
n=6 participants at risk
Single dose of placebo matching LY3084077 administered SC.
|
LY3084077 Cohort 2
n=6 participants at risk
1 mg single dose of LY3084077 administered SC.
|
LY3084077 Cohort 3
n=6 participants at risk
3 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 4
n=6 participants at risk
10 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 5
n=6 participants at risk
30 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 6
n=6 participants at risk
100 mg single dose of LY3084077 administered SC
|
LY3084077 Cohort 7
n=6 participants at risk
150 mg single dose of LY3084077 administered SC
|
|---|---|---|---|---|---|---|---|
|
General disorders
Thirst
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Infections and infestations
Dengue fever
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Infections and infestations
Influenza
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Infections and infestations
Upper respiratory tract infection
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Injury, poisoning and procedural complications
Procedural site reaction
|
50.0%
3/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
66.7%
4/6 • Number of events 6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
66.7%
4/6 • Number of events 4
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 4
All randomized participants who received at least one dose of study drug.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Eye disorders
Eyelid pain
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
50.0%
3/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
50.0%
3/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Colitis
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Diarrhoea
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
50.0%
3/6 • Number of events 4
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Catheter site erythema
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Catheter site haematoma
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Catheter site pain
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Early satiety
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Fatigue
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Feeling hot
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Injection site haematoma
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Injection site pain
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Pain
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
General disorders
Pyrexia
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Headache
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Increased upper airway secretion
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
50.0%
3/6 • Number of events 3
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
33.3%
2/6 • Number of events 2
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6
All randomized participants who received at least one dose of study drug.
|
Additional Information
Chief Medical Officer
Eli Lilly and Company
Phone: 800-545-5979
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place